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Purpose:  The aim of the present study is to investigate the physicochemical equivalence of 
eight brands of tablets containing sulfadoxine-pyrimethamine (antimalarial drug combination) 
sourced from different retail Pharmacy outlets in the Nigerian market. 
Method:   The quality and physicochemical equivalence of eight different brands of 
sulfadoxine-pyrimethamine combination tablets were assessed. The assessment included the 
evaluation of uniformity of weight, friability, crushing strength, disintegration and dissolution 
tests as well as chemical assay of the tablets.  
Results:  All the eight brands of the tablets passed the British Pharmacopoeia (BP) standards 
for uniformity of weight, disintegration and crushing strength. Three of the eight brands failed 
the friability test. One of the brands did not comply with the standard assay of content of 
active ingredients while another brand did not comply with the USP specifications for 
dissolution test for sulfadoxine-pyrimethamine tablets. There were no significant differences in 
the amounts of pyrimethamine and sulfadoxine released from the different brands (P>0.05).   
Conclusion: Only three brands (registered by NAFDAC) out of the eight brands of 
sulfadoxine-pyrimethamine tablets that were analysed passed all the BP quality specifications 
and were physically and chemically equivalent. This study highlights the need for constant 
market monitoring of new products to ascertain their equivalency to the innovator product. 
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Introduction 
The increase in the number of generic drug 
products from multiple sources has placed 
people involved in the delivery of health care 
in a position of having to select one from 
among several seemingly equivalent 
products. For instance, in 1975 
approximately 9% of all prescription drugs 
dispensed in the United States were generic 
versions1. This figure rose to 20% in 1984 
and 40% in 19912. Over 80% of the 
approximately 10,000 prescription drugs 
available in 1990 were obtained from more 
than one source and variable clinical 
responses to these dosage forms supplied 
by two or more drug manufacturers is 
documented2. These variable responses 
may be due to formulation ingredients 
employed, methods of handling, packaging 
and storage and even the rigors of in-
process quality control. Thus, there is need 
to determine their pharmaceutical and 
therapeutic equivalence in order to ensure 
interchangeability.  
However, many developing countries do not 
have an effective means of monitoring the 
quality of generic drug products in the 
market. This results in widespread 
distribution of substandard and/or counterfeit 
drug products. It was in view of this fact that 
the World Health Organization issued 
guidelines for global standard and 
requirements for the registration, 
assessment, marketing, authorization and 
quality control of generic pharmaceutical 
products3. This was to give technical 
guidelines to national regulatory authorities 
such as NAFDAC (National Agency for 
Food, Drug, Administration and Control), 
which is responsible for drug administration 
and control in Nigeria, on the quality of drug 
dosage forms generally available in the 
market. Generic drug products must satisfy 
the same standards of quality, efficacy and 
safety as those applicable to the innovator 
products. Preliminary physicochemical 
assessment of the products is very important 
and in vitro dissolution testing can be a 
valuable predictor of the in vivo 
bioavailability and bioequivalence of oral 
solid dosage forms4. 
Sulfadoxine-pyrimethamine (500 mg and 25 
mg, respectively) combination tablets are 
commonly used for the prophylaxis and 
suppression of chloroquine-resistant 
Plasmodium falciparum malaria, which is a 
cause of high mortality among children in 
tropical Africa. The action of the sulfadoxine 
component is due to its effect in potentiating 
the effect of pyrimethamine. This action is 
presumably due to sequential blockade of 
different stages in plasmodial synthesis of 
nucleotides5.  Apart from Fansidar (Roche 
Pharmaceuticals, Lagos), which is an 
expensive innovator product, several generic 
antimalarials are marketed in Nigeria that are 
generally less expensive. Hence there is the 
need to assess the bioequivalence of these 
generic products with the innovator product. 
Thus, in the present study the equivalence of 
eight brands (including the innovator 
product) of sulfadoxine-pyrimethamine 
tablets sourced from retail pharmacies in 
Ibadan, Nigeria was determined using in 
vitro methods.    This preliminary study is 
aimed at obtaining baseline data towards the 







Eight brands of Sulfadoxine-pyrimethamine 
tablets (A to H) were obtained from different 
retail outlets in Nigeria. The manufacture and 




  Twenty tablets selected at random were 
weighed individually and their average 
weight calculated to determine the weight 
uniformity6. The percentage deviation of 
each tablet from the average weight was 
determined. Twenty tablets were caused to 
cascade in a friabilator (Erweka TA, 
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Germany) rotated at 25 rpm for 4 min. The 
weight loss was determined as a percentage 
of the initial weight. 
 
Crushing strength of each of 9 tablets per 
brand was determined using the PTB 301 
hardness tester (Pharmatest, Switzerland). 
The load required to break the tablets into 
two halves was determined.  
 
The disintegration times of six tablets per 
brand were determined in distilled water at 
37 ± 0.5 oC using the Apex Tablet 
Disintegration Apparatus (Apex Construction 
Ltd., Kent, U.K). Determinations were done 
in triplicate. 
 
Dissolution tests on the tablets were carried 
out using the Hanson Easy Lift Dissolution 
Station Apparatus (Hanson Research 
laboratories, London, U.K) fitted with a 
basket rotated at 75 rpm6.  The buffer (500 
ml), pH 6.8, was poured into the vessel 
maintained at 37±0.5 oC. One tablet of each 
brand was placed in the basket and lowered 
into the vessel containing the dissolution 
medium. Samples (5 ml) were withdrawn at 
timed intervals and replaced with fresh 
dissolution medium. The samples were 
filtered and diluted appropriately with the 
buffer solution and the absorbance of the 
solution was measured at 220 nm for 
sulfadoxine and 288 nm for pyrimethamine. 
The regression equation for the calibration 
curves prepared for each drug component in 
phosphate buffer pH 6.8 was y = 0.016x + 
0.007, r2 = 0.99; and y = 0.200x + 0.002, r2 = 
0.99 for pyrimethamine and sulfadoxine, 
respectively. 
 
The graph of the amount of sulfadoxine and 
pyrimethamine dissolved versus time were 
plotted from which T50 and T70 (the time 
required for 50% and 70% of the active drug 
to be dissolved respectively) and amount 
dissolved at 30 min were obtained for each 
brand. Determinations were done in 
triplicate.  
 
Assay of Active ingredient 
 
Pyrimethamine: Twenty tablets were 
weighed and powdered. Hot 0.1 M HCl (25 
ml) was added to 225 mg of powder 
containing 12.5 mg pyrimethamine. This was 
heated on a water bath for 30 min, with 
occasional swirling. It was then placed in an 
ultrasonic bath for 30 min, removed and 
cooled to room temperature. Sufficient 
quantity of 0.1 M HCl was added to produce 
50 ml. The solution was filtered and 2.5 ml of 
the filtrate was diluted with 0.1 M HCl to 
produce 50 ml. The amount of 
pyrimethamine was determined at 288 nm 
using a Lambda 3B UV-visible spectro-
photometer (Perkin-Elmer, USA). 
Table 1: Country of origin, manufacture and expiry dates of eight brands of sulfadoxine-
pyrimethamine tablets 
 
Brand Date of Manufacture Expiry Date Country of Origin NAFDAC* Registration 
A March, 2000 March, 2005 Nigeria Yes 
B June, 1999 June, 2003 United Kingdom Yes 
C January, 2000 August, 2002 India No 
D February, 2000 January, 2004 India No 
E January, 1999 December, 2002 India Yes 
F February, 1999 January, 2003 India Yes 
G March, 2000 December, 2003 India No 
H January, 2000 December, 2003 India No 
*National Agency for Food and Drugs Administration and Control, Abuja, Nigeria 
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Sulfadoxine: The amount of sulfadoxine 
present in tablet was assayed using the BP 
1998 method. Twenty tablets were dissolved 
in 50 ml of 2 M HCl and 3 g of potassium 
bromide was added. The resulting solution 
was cooled in iced water and titrated slowly, 
adding 0.1 M sodium nitrite VS with constant 
stirring. The end point was determined using 
starch iodide paper6. Sodium nitrite (1 ml of 





Data for weight uniformity test, friability, 
crushing strength and the disintegration and 
dissolution times of the tablets were 
analysed by determining the mean ± 
standard deviation. 
 
Statistical analysis: The statistical 
significance difference in the amount of 
sulfadoxine and pyrimethamine released 
from each brand compared with the 
innovator product was carried out with 
Student T-test using Microsoft Excel 
software. At 95% confidence interval, 2-
tailed p values less than or equal to 0.05 
were considered significant.  
 
 
Results and Discussion 
 
All the samples used for the study were 
within their shelf life at the time of 
investigation. Four out of the eight brands of 
the sulfadoxine-pyrimethamine tablets have 
been registered by NAFDAC. The results of 
the physicochemical properties of the 
various brands of sulfadoxine-pyrimethamine 
are presented in Table 2. All brands showed 
acceptable uniformity of weight as none had 
percent deviation in weight greater than 5% 
as stipulated by the British Pharmacopoeia 
19986. The significance of this test is to 
ensure that the tablets in each Lot are within 
the appropriate size range. 
 
The crushing strength of the tablets is an 
essential criterion in the determination of the 
ability of the tablets to resist chipping, 
abrasion or breakage under conditions of 
storage, transportation and handling before 
storage. The results showed that the brands 
examined had mean crushing strength within 
the range of 7.8 - 15.68 kgF. Generally, a 
hardness of 4 kgF is normally considered to 
be minimum for a satisfactory tablet7, 9. 
 
Table 2: Physicochemical properties of eight brands of sulfadoxine-pyrimethamine tablets 
 Parameter Weight uniformity     
Test, mg (mean ± sd) 
Friability, % loss 
(mean ± sd)   
Crushing 
strength, KgF 
(mean ± sd) 
Disintegration             
time, min 
(mean ± sd) 
Brand A 538.8±9.2 0.2±0.01 15.7±1.7 1.8±1.0 
Brand B 527.4±1.0 0.1± 0.1 11.2±0.8 8.3±1.2 
Brand C 526.5±30.9 1.2 ± 0.2* 14.3±2.3 4.4±0.5 
Brand D 525.7±17.9 0.4 ±0.1 15.3±0.4 2.2±0.9 
Brand E 525.7±17.4 1.5± 0.1* 7.8±1.6 2.5±1.0 
Brand F 527.3±15.7 0.7±0.1 13.7±3.0 2.0±0.8 
Brand G 526.1±17.5 0.5 ± 0.1 12.1±3.1 3.1±1.4 
Brand H 521.7±13.6 1.2 ± 0.2* 12.5±0.8 2.5±0.1 
*Failed to meet BP specifications 
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Another tablet property related to crushing 
strength is friability, which is designed to 
evaluate the ability of the tablet to withstand 
abrasion during packaging, handling and 
shipping. For compressed tablets, 
percentage loss in weight of less than 1% is 
usually considered acceptable9.  The results 
showed that brands A, B, D, F and G 
conformed to the required standard for 
friability, while brands C, E and H failed to 
comply. This failure could have resulted from 
the use of inadequate or insufficient amount 
of binding agent during formulation, 
inadequate moisture content during 
compression or insufficient compression 
pressure during tableting. 
 
The disintegration test measures the time 
required for tablets to disintegrate into 
particles. This is a necessary condition for 
dissolution and could be the rate-determining 
step in the process of drug absorption. The 
BP 1998 stipulates a disintegration time of 
not more 15 min for uncoated tablets. The 
results of the disintegration test are 
presented in Table 2. The results showed 
that all the brands passed the disintegration 
test. 
 
The results of the assays of chemical 
content to determine the amount of 
sulfadoxine and pyrimethamine present in 
each formulation are presented in Table 3. 
They showed that all the brands contain 
between 90% and 110% of the labelled 
amount specified for sulfadoxine5. There was 
no statistically significant difference between 
the different brands of the drug and the 
innovator product, A. Furthermore, all the 
brands of the tablets except brand D passed 
the test for the content of pyrimethamine. 
The pyrimethamine content of brand D was 
141.2% which was significantly different from 
the innovator product, A (p < 0.05). This 
could be due to poor preparation techniques 
during formulation and subsequent 
manufacturing. An important character of 
powders during mixing is segregation, which 
occurs due to differences in particle size. 
Furthermore, the amount of pyrimethamine 
in the combination tablet is relatively small 
(i.e. 25 mg), which means any demixing or 
segregation during processing will result in 
non-uniformity of content. 
 
The dissolution test is a measure of the 
amount of the drug released into the 
dissolution medium with time. The United 
States Pharmacopoeia stipulates that at 30 
min, all tablets should have released into the 
dissolution medium an amount not less than 
60% of the labelled amount of sulfadoxine 
and pyrimethamine.  The dissolution profiles 
of pyrimethamine and sulfadoxine in all 
brands are presented in Figures 1 and 2, 
respectively. The time for 50% and 70% (T50 
and T70, respectively) of drug to be released 
and the amount of drug released at 30 min 
are presented in Table 4. All the brands 
passed the dissolution test except brand G 
which showed only 58.6% and 52.8% of 
sulfadoxine and pyrimethamine released, 
respectively at 30 min. This may be due to 
the nature of excipients used or the 
formulation process. It has been shown by 
Abdou10 that the dissolution rate of a pure 
drug can be altered significantly when mixed 
with various adjuncts during the 
manufacturing process of solid dosage 
forms. Furthermore, the fast disintegrating 
Table 3: Content of sulfadoxine and 
pyrimethamine in the combination tablets 
 
 %w/w  (mean + sd) 
Brand 
Code 
Sulfadoxine  Pyrimethamine 
A 102.4 ± 0.1 102.2 ± 1.1 
B 102.9 ± 0.1 99.0 ± 0.6 
C 103.5 ± 0.1 102.3 ± 1.1 
D 101.8 ±  0.1 141.2 ± 2.1* 
E 102.4 ± 0.1 99.8 ± 0.6 
F 101.2 ± 0.1 103.1 ± 1.2 
G 102.5 ± 0.1 92.0 ± 0.0 
H 101.3 ± 0.1 105.1 ± 0.1 
*Failed to meet BP specifications 
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characteristics of Brand G is not reflected in 
the dissolution profile. This could be due to 
the fact that the disintegrated particles 
though small enough to pass through the 
screen of the dissolution basket, may have 
retained the active drug within their hard 
cores and hence did not release the drug 
into the dissolution medium. This implies that 
the product may not release a significant 
amount of the drug on absorption into the 





















Figure 1: Dissolution profiles of pyrimethamine 
from eight different brands of sulfadoxine-
pyrimethamine tablets in phosphate buffer pH 6.8 
Figure 2: Dissolution profiles of sulfadoxine from 
eight different brands of sulfadoxine-



















Table 4: Dissolution parameters of the eight brands of sulfadoxine-pyrimethamine tablets  
(mean ± sd) 
 
T50 (min) T70 (min) % Dissolved at 30 min  
Product Sulfadoxine Pyrimethamine Sulfadoxine Pyrimethamine Sulfadoxine Pyrimethamine 
A 4.8 ± 0.2 6.0 ± 2.2 10.0 ± 2.1 18.0 ± 3.1 88.7 ± 1.4 71.8 ± 2.8 
B 6.0 ± 1.2 12.0 ± 0.3 29.5 ± 1.3 62.4 ± 1.7 70.6 ± 2.1 61.3 ± 0.8 
C 5.4 ± 0.1 4.9 ± 2.4 29.3 ± 0.5 68.2 ± 1.8 72.6 ± 1.6 67.4 ± 1.5 
D 9.8 ± 3.1 12.0 ± 1.2 65.0 ± 2.4 68.0 ± 0.4 63.3 ± 1.1 68.3 ± 3.2 
E 5.5 ± 2.3 10.0 ± 3.2 68.2 ± 2.1 66.0 ± 0.5 64.4 ± 0.3 64.4 ± 1.5 
F 7.0 ± 2.3 8.0 ± 2.1 30.0 ± 2.4 20.0 ± 2.9 71.9 ± 2.8 71.2 ± 4.1 
G 9.8 ± 3.5 18.0 ± 1.5 58.5 ± 3.4 52.0 ± 1.4 58.6 ± 0.7 52.8 ± 1.7* 
H 7.0 ± 2.1 6.0 ± 0.2 64.0 ±1.6 64.0 ± 2.2 63.1 ± 2.4 62.8 ± 2.9 
*Failed to meet USP specification 
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Conclusion  
 
Only three brands (registered by NAFDAC) 
out of the eight brands of sulfadoxine-
pyrimethamine tablets analysed passed all 
the BP quality specifications and were 
physically and chemically equivalent. These 
three brands can be substituted for each 
other in their prescription and use. 
This study highlights the problems 
associated with a multi-component dosage 
form especially one like the sulfadoxine-
pyrimethamine combination where the 
efficacy of the formulation depends on the 
precise amount of the active ingredients 
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